Pediatric Growth Hormone Deficiency Market Report 2026

The pediatric growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.15 billion in 2025 to $4.52 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to limited awareness of gh deficiency, reliance on conventional therapies, fragmented pediatric endocrinology care, minimal use of digital monitoring, low adoption of long-acting gh formulations.

The pediatric growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $6.32 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growing adoption of rhgh therapy, increasing development of long-acting gh analogs, rising focus on personalized treatment plans, increasing integration of digital patient monitoring solutions, growing regulatory support for pediatric endocrine therapies. Major trends in the forecast period include increasing adoption of recombinant human growth hormone therapy, rising use of long-acting growth hormones, growing integration of digital tools for patient monitoring, increasing implementation of ai-based diagnostic and treatment planning, rising focus on precision medicine approaches in pediatric gh deficiency.

The rising prevalence of pediatric diseases is expected to contribute significantly to the growth of the pediatric growth hormone deficiency market going forward. Pediatric diseases encompass a broad range of conditions affecting children from infancy through adolescence. Their increasing incidence is linked to factors such as environmental influences, improved diagnostic practices, lifestyle changes, genetic susceptibility, and higher rates of chronic conditions and allergies among children. Certain pediatric illnesses can impair the hypothalamus or pituitary gland, which play a central role in growth hormone production, thereby increasing the risk of growth hormone deficiency. For example, in August 2024, the United Nations Children’s Fund reported that approximately 1.1 million children and adolescents aged 0 to 19 years worldwide are living with type 1 diabetes and require daily insulin to survive, with many in low- and middle-income countries lacking access to essential care. As a result, the growing burden of pediatric diseases is supporting market growth.

Companies operating in the pediatric growth hormone deficiency market are increasingly concentrating on the development of innovative long-acting, once-weekly human growth hormone analogs to enhance treatment convenience and patient adherence. These therapies are designed to remain active in the body for extended periods compared to traditional daily injections. In June 2023, Pfizer Inc. and OPKO Health Inc. announced the approval of NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog for pediatric patients aged three years and older with growth failure caused by insufficient endogenous growth hormone secretion. This therapy demonstrated efficacy comparable to daily growth hormone treatments in clinical trials while reducing injection frequency, offering a more manageable option for children and caregivers.

In December 2024, Double Point Ventures, a US-based venture capital firm, acquired Lumos Pharma for $38 million. Through this acquisition, Double Point Ventures aims to accelerate the development of Lumos Pharma’s lead therapeutic candidate, LUM-201, and broaden its portfolio of rare disease treatments. Lumos Pharma is a US-based biopharmaceutical company focused on developing therapies for rare conditions, particularly those associated with growth hormone deficiencies.

Major companies operating in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Ipsen Pharma, Ferring Pharmaceuticals, OPKO Health Inc., Ascendis Pharma A/S, Versartis Inc., LG Chem Ltd., GeneScience Pharmaceuticals Co Ltd, Biopartners GmbH, JHM Biopharma, JCR Pharmaceuticals Co Ltd, Samsung Bioepis, Intas Pharmaceuticals Ltd, BioMarin Pharmaceutical Inc, Abbott Laboratories, Amgen Inc, Chugai Pharmaceutical Co Ltd, Sanofi S A, AnkeBio Co Ltd, Zhongshan Sinobioway Hygene Biomedicine Co Ltd.

North America was the largest region in the pediatric growth hormone deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric growth hormone deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pediatric growth hormone deficiency market by increasing costs for imported recombinant hormones, delivery devices, and ancillary medical equipment, particularly impacting regions like North America and Europe. The higher import duties have slowed product adoption in hospital pharmacies and retail pharmacies. However, tariffs have also encouraged local manufacturing of growth hormones and devices, fostering innovation and reducing dependency on international suppliers, benefiting domestic players.

The pediatric growth hormone deficiency market research report is one of a series of new reports that provides pediatric growth hormone deficiency market statistics, including pediatric growth hormone deficiency industry global market size, regional shares, competitors with a pediatric growth hormone deficiency market share, detailed pediatric growth hormone deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric growth hormone deficiency industry. This pediatric growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric growth hormone deficiency (PGHD) is a disorder in which the pituitary gland fails to secrete adequate amounts of growth hormone, resulting in reduced growth velocity, short stature, and delayed pubertal development in children. The condition may be present at birth or develop later in childhood, and management generally involves treatment with recombinant human growth hormone therapy to promote normal physical growth and development.

The key forms of pediatric growth hormone deficiency include congenital growth hormone deficiency, acquired growth hormone deficiency, and idiopathic growth hormone deficiency. Congenital growth hormone deficiency is an uncommon condition characterized by an inability to produce sufficient growth hormone from birth. Available treatments comprise several product categories such as recombinant human growth hormone, human growth hormone analogs, and long-acting growth hormone formulations, which are administered through routes including subcutaneous, intramuscular, and oral delivery. These therapies are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are used across multiple indications including growth hormone deficiency, idiopathic short stature, Turner syndrome, small for gestational age, and Prader-Willi syndrome.

The pediatric growth hormone deficiency market consists of sales of synthetic growth hormone, growth hormone releasing hormone, and long-acting growth hormone therapies. Values in this market are factory gate values, representing the value of goods sold by manufacturers or creators of the goods to other entities such as distributors and retailers or directly to end customers. The market value includes related services sold by the creators of these goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.